Featured Research

from universities, journals, and other organizations

NIMH Study Finds Antipsychotic Risperidone Safe, Effective As Intermediate Term Treatment For Autism

July 6, 2005
University of California - Los Angeles
A multi-site research group working under contract with NIMH finds that Risperidone, one of the newer anti-psychotic medications, is safe and effective for controlling aggressive and violent behavior in autistic children with minimal side effects for up to six months. The medication also decreases repetitive behaviors and increases social interaction with these children. The study appears in upcoming American Journal of Psychiatry.

A multi-site study sponsored by the National Institute of Mental Health (NIMH) finds children with autism characterized by tantrums, aggression, and/or self-injury respond favorably to the antipsychotic medication risperidone for up to six months.

Published in the July edition of the American Journal of Psychiatry, the study found the medication not only decreased aggression but also reduced repetitive behaviors and increased social interaction -- all with limited side effects. The two-part study also found discontinuation after six months prompted rapid return of disruptive and aggressive behavior in most cases.

Atypical antipsychotic medications such as risperidone are of interest to doctors who treat children with autism because studies show the newer medications benefit adults with schizophrenia with fewer neurological side effects than older options.

"A variety of treatments, including medication, are used to manage aggressive behaviors in autistic children, but controlled medication trials are limited," said Dr. James McCracken, lead author and site investigator at the Semel Institute for Neuroscience and Human Behavior at UCLA. "Our findings support adding risperidone to the small arsenal of intermediate-term medication options for the tens of thousands of children with autism who display aggressive and destructive behaviors.

"The response to risperidone ranks among the most positive ever observed in children with autism for a drug treatment," said McCracken, a professor of psychiatry and biobehavioral sciences and director of the Division of Child and Adolescent Psychiatry at the David Geffen School of Medicine at UCLA.

Autism is a chronic condition that appears in early childhood. Core symptoms include impaired social interaction, delayed language development and restricted patterns of behavior. The disorder affects as many as 20 in 10,000 children. Although the causes of autism are unknown, scientific evidence point to abnormalities in brain development and a strong genetic component.

In addition to core symptoms, children with autism frequently exhibit serious behavior disturbances in response to routine environmental demands. For these disturbances, behavior therapy and medications are the two main forms of treatment.

In the multi-site study, researchers randomly assigned 101 subjects -- 82 boys and 19 girls -- ages 5 to 17 to receive either placebo or risperidone. Subjects who improved substantially after eight weeks continued treatment for up to six months. Researchers observed a small sample of subjects at the end of the study during the withdrawal of the medication.

Previously, the largest extended studies of medication for autism with haloperidol, an older antipsychotic, showed the drug to be modestly effective but accompanied by neurological and other side effects.

Past research into the effect of risperidone on children with autism found the medication effective for short-term treatment of aggressive behaviors related to autism in children. Side effects to risperidone are usually well-tolerated, with some complaints of weight gain.

The intermediate-term risperidone study was conducted at five sites of the Research Units of Pediatric Psychopharmacology (RUPP) network, which is funded by NIMH. The RUPP network is composed of research units devoted to conducting studies to test the efficacy and safety of medications commonly used off-label to treat children and adolescents. In clinical practice, many medications are used in the treatment of autism, but few medications have been carefully studied to determine the safety and effectiveness of the medication for the treatment of childhood illnesses.

Principal investigators at other research sites included Michael G. Aman of Ohio State University, Dr. Christopher J. McDougle of Indiana University, Lawrence Scahill of Yale University, Elaine Tierney of Kennedy Krieger Institute at Johns Hopkins University, and Dr. Benedetto Vitiello of the NIMH. Faculty at Columbia University, Yale University and Nathan Kline Institute participated in data collection, coordination and analysis.


Funding for the study was provided by the National Institute of Mental Health, National Institutes of Health Division of Research Resource General Clinical Research Center, and the Korczak Foundation. Study medications were donated by Janssen Pharmaceutica.

The Semel Institute for Neuroscience and Human Behavior at UCLA is an interdisciplinary research and education institute devoted to the understanding of complex human behavior, including the genetic, biological, behavioral and sociocultural underpinnings of normal behavior, and the causes and consequences of neuropsychiatric disorders. More information about the Institute is available online at www.npi.ucla.edu.

Story Source:

The above story is based on materials provided by University of California - Los Angeles. Note: Materials may be edited for content and length.

Cite This Page:

University of California - Los Angeles. "NIMH Study Finds Antipsychotic Risperidone Safe, Effective As Intermediate Term Treatment For Autism." ScienceDaily. ScienceDaily, 6 July 2005. <www.sciencedaily.com/releases/2005/07/050706001911.htm>.
University of California - Los Angeles. (2005, July 6). NIMH Study Finds Antipsychotic Risperidone Safe, Effective As Intermediate Term Treatment For Autism. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2005/07/050706001911.htm
University of California - Los Angeles. "NIMH Study Finds Antipsychotic Risperidone Safe, Effective As Intermediate Term Treatment For Autism." ScienceDaily. www.sciencedaily.com/releases/2005/07/050706001911.htm (accessed August 27, 2014).

Share This

More Mind & Brain News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Stroke in Young Adults

Stroke in Young Adults

Ivanhoe (Aug. 27, 2014) A stroke can happen at any time and affect anyone regardless of age. This mother chose to give her son independence and continue to live a normal life after he had a stroke at 18 years old. Video provided by Ivanhoe
Powered by NewsLook.com
Distracted Adults: ADHD?

Distracted Adults: ADHD?

Ivanhoe (Aug. 27, 2014) Most people don’t realize that ADHD isn’t just for kids. It can affect the work as well as personal lives of many adults, and often times they don’t even know they have it. Video provided by Ivanhoe
Powered by NewsLook.com
The Sight and Sounds of Autism

The Sight and Sounds of Autism

Ivanhoe (Aug. 27, 2014) A new study is explaining why for some people with autism what they see and what they hear is out of sync. Video provided by Ivanhoe
Powered by NewsLook.com
Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins